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Abstract
Introduction In critical illness, the association of hypoglycemia,
blood glucose (BG) variability and outcome are not well
understood. We describe the incidence, clinical factors and
outcomes associated with an early hypoglycemia and BG
variability in critically ill patients.
Methods Retrospective interrogation of prospectively collected
data from the Australia New Zealand Intensive Care Society
Adult Patient Database on 66184 adult admissions to 24
intensive care units (ICUs) from 1 January 2000 to 31
December 2005. Primary exposure was hypoglycemia (BG <
4.5 mmol/L) and BG variability (BG < 4.5 and ≥ 12.0 mmol/L)
within 24 hours of admission. Primary outcome was all-cause
mortality.
Results The cumulative incidence of hypoglycemia and BG
variability were 13.8% (95% confidence interval (CI) = 13.5 to
14.0; n = 9122) and 2.9% (95%CI = 2.8 to 3.0, n = 1913),
respectively. Several clinical factors were associated with both
hypoglycemia and BG variability including: co-morbid disease
(P < 0.001), non-elective admissions (P < 0.001), higher illness
severity (P < 0.001), and primary septic diagnosis (P < 0.001).
Hypoglycemia was associated with greater odds of adjusted
ICU (odds ratio (OR) = 1.41, 95% CI = 1.31 to 1.54) and
hospital death (OR = 1.36, 95% CI = 1.27 to 1.46).
Hypoglycemia severity was associated with 'dose-response'
increases in mortality. BG variability was associated with greater
odds of adjusted ICU (1.5, 95% CI = 1.4 to 1.6) and hospital
(1.4, 95% CI = 1.3 to 1.5) mortality, when compared with either
hypoglycemia only or neither.
Conclusions In critically ill patients, both early hypoglycemia
and early variability in BG are relatively common, and
independently portend an increased risk for mortality.
Introduction
Elevated blood glucose (BG) levels and stress-hyperglycemia
have been identified as modifiable risk factors for adverse out-
comes in critically ill patients. [1]. Randomized trials of inten-
sive monitoring and insulin therapy (IIT) in critically ill patients
have been performed showing improvements in morbidity and
mortality with tight glycemic control (TGC) [2-6]. Data from
selected trials suggest that, for TGC to exert its clinical bene-
fit, BG values must be maintained in the range of 4.4 to 6.1
mmol/L [4,5]. Based on this evidence, use of IIT to achieve
TGC has been widely advocated to improve outcomes for crit-
ically ill patients [7,8]. Recently, however, the findings of the
multi-center multi-national NICE-SUGAR (Normglycemia in
Intensive Care Evaluation – Survival Using Glucose Algorithm
AKI: acute kidney injury; ANZICS: Australian and New Zealand Intensive Care Society; APACHE: Acute Physiology and Chronic Health Evaluation; 
APD: Adult Patient Database; AuROC: area under the receiver operator characteristic curve; BG: blood glucose; CI: confidence interval; CORE: 
Clinical Outcomes and Resource Evaluation; GCS: Glasgow Coma Scale; IIT: intensive insulin therapy; ICU: intensive care unit; IQR: intra-quartile 
range; OR: odds ratio; SD: standard deviation; TGC: tight glycemic control.Critical Care    Vol 13 No 3    Bagshaw et al.
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Regulation) randomized trial, comparing IIT with less-intensive
insulin therapy in 6104 critically ill patients, have suggested
the use of IIT is associated with a higher 90-day mortality
(27.5% vs. 24.9%; odds ratio (OR) = 1.14, 95% confidence
interval (CI) = 1.02 to 1.28, P = 0.02). [9].
Accordingly, the issue of TGC remains controversial [10-17].
Concerns have arisen that TGC may be associated with unac-
ceptably high rates of hypoglycemia [18]. In the two TGC trials
in surgical and medical patients from the University of Leuven,
hypoglycemia (BG < 2.2 mmol/L) occurred in 5.1% and
18.7% of patients, respectively [4,5]. Recently, the VISEP
(Volume Substitution and Insulin Therapy in Severe Sepsis)
trial, a multi-center randomized trial comparing IIT with conven-
tional therapy in critically ill septic patients, was terminated
early due to a lack of evidence of survival benefit with IIT and
a significantly higher incidence of hypoglycemia in those allo-
cated to IIT (17.0% vs. 4.1%, P < 0.001). [19]. Likewise, in the
NICE-SUGAR trial, IIT was associated with greater hypoglyc-
emia (6.8% vs. 0.5%, P < 0.001) compared with conventional
glycemic control. Hypoglycemia in critically ill patients may
have unrecognized clinical importance. Observational data
have indicated that even a single episode of hypoglycemia
may be associated with worse clinical outcomes. [20]. Also,
variability in glycemic control has increasingly been recog-
nized as having a potentially important association with clinical
outcome [21-24].
Accordingly, we searched the Australian and New Zealand
Intensive Care Society (ANZICS) Clinical Outcomes and
Resource Evaluation (CORE) Adult Patient Database (APD) to
obtain information on BG measures within 24 hours of inten-
sive care unit (ICU) admission in a large cohort of ICU patients
from 24 ICUs over a six-year period [25]. Our objectives were
to: describe the incidence of and clinical factors associated
with an early episode of hypoglycemia and BG variability
(within 24 hours of ICU admission) in critically ill patients; eval-
uate any association between early hypoglycemia, BG variabil-
ity, and mortality; and evaluate any association between
severity of early hypoglycemia and mortality.
Materials and methods
Study population
This was a retrospective analysis of prospectively collected
data. We searched the ANZICS CORE APD for all adult (age
≥ 18 years) ICU admissions from 1 January 2000 to 31
December 2005. Patients were excluded if data on either BG
or outcome were unavailable (7.5%, n = 5329). The ANZICS
CORE APD captures clinical, physiologic, and laboratory data
for the initial 24 hours of ICU admission for those with a dura-
tion of stay of 24 hours or longer, along with outcome data and
vital status at hospital discharge. This comprised data from 24
ICUs (10 tertiary referral, 7 metropolitan, 5 regional/rural, and
2 private hospitals) that contributed data over these consecu-
tive years.
Access to the data was granted by the ANZICS CORE Man-
agement Committee in accordance with standing protocols.
Local hospital Research Ethics Board approval was waived.
By government legislation, investigators are allowed to use de-
identified data from the APD for the purpose of epidemiologic
research so long as it is approved by the CORE Management
Committee. Such data are collected and transferred from hos-
pitals to the database under government support and funding
with each hospital allowing such transfer and subsequent data
use as necessary.
Blood glucose measures
The APD prospectively captures data on highest (BGHIGH) and
lowest (BGLOW) BG concentrations within the initial 24 hours
of ICU admission. All BG values entered into the database are,
for the vast majority of patients, obtained via blood gas analyz-
ers and reflect whole BG values. For each patient, we
extracted data on the BGHIGH and BGLOW. We calculated the
average BG concentration (BGAVE) for the first 24 hours as the
mean of the BGHIGH and BGLOW. This BGAVE may not be rep-
resentative of the true BGAVE for those patients having had
multiple BG measurements in the first 24 hours.
An episode of hypoglycemia was defined by a documented
BG of less than 4.5 mmol/L. Hypoglycemia was further strati-
fied into six mutually exclusive groups of severity by dividing
BGLOW into the following categories: less than 2.0 mmol/L;
2.0 to 2.4 mmol/L; 2.5 to 2.9 mmol/L; 3.0 to 3.4 mmol/L; 3.5
to 3.9 mmol/L; 4.0 to 4.4 mmol/L; and 4.5 mmol/L or higher.
An elevated BG was defined by a documented BG of more
than 6.1 mmol/L. We defined early BG variability as any
patient who had both an episode of hypoglycemia (BG < 4.5
mmol/L) and hyperglycemia (BG ≥ 12.0 mmol/L) within 24
hours of ICU admission [23].
Data from a large multi-center survey of practice found less
than 10% of all ICUs in ANZICS had adopted TGC protocols
with IIT following the reporting of the trial by van den Berghe
and colleagues [26]. Accordingly, the hypoglycemia occurring
in the majority of patients in this study was more likely to be
related to primary diagnosis or illness severity rather than IIT.
Data collection
Standard demographic, clinical, and physiologic data were
retrieved. Demographic information included age, sex, and
dates and sources of admissions. Clinical data encompassed
primary diagnosis, surgical status, co-morbidities, need for
mechanical ventilation, and evidence of acute kidney injury
(AKI), defined by the RIFLE classification scheme. [27]. Phys-
iologic data included Glasgow Coma Scale (GCS), vital signs,
and urine output. Laboratory data included routine hematology
and blood chemistry. Severity of illness was assessed using
the Acute Physiology and Chronic Health Evaluation
(APACHE) II and III score. The operational definitions for pre-Available online http://ccforum.com/content/13/3/R91
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existing co-morbidities and primary diagnostic categories are
shown in Additional data file 1.
Outcomes
Outcomes extracted included ICU and hospital mortality. If
patients were readmitted to ICU prior to hospital discharge,
subsequent ICU admissions were not included in the analysis
of mortality.
Statistical analysis
The cumulative incidence of early hypoglycemia was calcu-
lated by dividing the total number of patients with a docu-
mented BG less than 4.5 mmol/L by the number of ICU
admissions over the five-year study, and is expressed as a pro-
portion (%) with 95% CI. This was similarly performed for BG
variability.
We used descriptive statistics to compare the demographic
characteristics, clinical factors, and crude outcomes among
patients with and without an episode of hypoglycemia. Nor-
mally or near normally distributed variables are reported as
means with standard deviations (SD) and compared by Stu-
dent's t-tests. Non-normally distributed continuous data are
reported as medians with inter-quartile ranges (IQR) and com-
pared by Mann Whitney U tests. Differences in proportions
among categorical data were assessed using Fisher's exact
tests for pair-wise comparisons and chi-squared tests for mul-
tiple groups.
The primary outcomes for this study were ICU and hospital
mortality. We evaluated the association of both a discrete epi-
sode of hypoglycemia, the severity of hypoglycemia, and BG
variability on ICU and hospital mortality by multi-variable logis-
tic regression analysis for the entire cohort, and for two a priori
selected subgroups in those with hypoglycemia: those with a
primary septic diagnosis, and mechanically ventilated surgical
patients. Covariates were selected for inclusion in the models
and included age, sex, co-morbidity, non age-related APACHE
II score (subtraction of age-related points from full APACHE II
score). [28], surgical status, primary diagnosis, need for
mechanical ventilation, AKI, and hospital site. For each model,
calibration and discrimination were assessed by the good-
ness-of-fit test and area under the receiver operator character-
istic curve (AuROC), respectively. Data are presented as
crude and adjusted OR with 95% CI. In the event of missing
data values, data were not replaced or estimated. Analyzes
were performed with the use of Intercooled Stata Release 10
(Stata Corp, College Station, TX, USA). Two-sided P < 0.05,
unadjusted for multiple testing, were considered to indicate
statistical significance for all comparisons.
Results
During the six-year study period, 71,513 patients were admit-
ted to the 24 study ICUs for 24 hours or longer. Of these,
66,184 (92.5%) had complete data for both BG values and
clinical outcomes. There were 132,368 BG values in the
66,184 ICU patients. The mean (SD) BGAVE, BGHIGH, and
BGLOW were 8.7 (4.6) mmol/L, 10.5 (6.0) mmol/L, and 6.9
(4.1) mmol/L, respectively.
Hypoglycemia
The cumulative incidence of early hypoglycemia during the six-
year study was 13.8% (95% CI = 13.5 to 14.0; n = 9122).
The clinical characteristics, acute physiology, and crude out-
comes of patients with hypoglycemia are shown in Tables 1 to
3. In 2.1% (n = 1409) of the cohort (18.3% of those with doc-
umented hypoglycemia), two episodes of hypoglycemia
occurred within the first 24 hours.
Potential important clinical variables associated with early
hypoglycemia included female sex (OR = 1.25, 95% CI = 1.20
to 1.30) and having any co-morbid illness (OR = 1.13, 95% CI
= 1.09 to 1.18), specifically end-stage kidney disease (OR =
1.91, 95% CI = 1.78 to 2.05), liver disease (OR = 1.60, 95%
CI = 1.45 to 1.75), and being immune-compromised (OR =
1.22, 95% CI = 1.13 to 1.32). Medical (OR = 1.71, 95% CI
= 1.64 to 1.78), non-elective admissions (OR = 1.77, 95% CI
= 1.70 to 1.86) and those with higher severity of illness (OR =
1.22 per five-point increase in APACHE II, 95% CI = 1.21 to
1.24) were associated with higher odds of hypoglycemia. Pri-
mary admission diagnoses of sepsis (OR = 1.41, 95% CI =
1.36 to 1.47) and metabolic disturbance and/or poisoning
(OR = 1.77, 95% CI = 1.67 to 1.88) had the higher odds of
early hypoglycemia.
Early hypoglycemia was associated with higher crude ICU
(18.7% vs. 9.8%; OR = 2.11, 95% CI = 2.00 to 2.25) and
hospital (25.6% vs. 15.5%; OR = 1.87, 95% CI = 1.77 to
1.97) mortality rates (Table 3). This association remained evi-
dent in multi-variable analysis for both ICU (OR = 1.41, 95%
CI = 1.31 to 1.53) and hospital (OR = 1.35, 95% CI = 1.26
to 1.45) mortality.
Those patients having two episodes of hypoglycemia within
24 hours of ICU admission had significantly higher crude and
covariate-adjusted ICU and hospital mortality compared with
only one episode or no hypoglycemia, respectively (Table 4).
The occurrence of hypoglycemia stratified by degree of
hypoglycemia is shown in Figure 1. Adjusted estimates of ICU
and hospital mortality stratified by severity of hypoglycemia are
shown in Tables 4 to 6. Increasing severity of hypoglycemia
was associated with a 'dose-response' increase in crude and
adjusted ICU and hospital mortality. Similar dose-response
associations between severity of hypoglycemia and mortality
were also apparent in the septic and mechanically ventilated
surgical subgroups.Critical Care    Vol 13 No 3    Bagshaw et al.
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Blood glucose variability
In total, 23% (95% CI = 22.7 to 23.3, n = 15229) of patients
had evidence of hyperglycemia (BG ≥ 12 mmol/L) within 24
hours of ICU admission. The cumulative incidence of early BG
variability, defined by the presence of both hypoglycemia and
hyperglycemia within 24 hours of ICU admission, was 2.9%
(95% CI = 2.8 to 3.0, n = 1913; Table 4). When compared
with patients with either hypoglycemia only or neither, those
experiencing BG variability were older (P  < 0.001), had a
higher burden of co-morbid disease (P < 0.001), had higher
illness severity (P < 0.001), were more likely to be non-elective
admissions (P < 0.0001), and were significantly more likely to
receive mechanical ventilation (P < 0.001).
BG variability was also associated with higher crude and cov-
ariate-adjusted ICU and hospital mortality when compared
with either hypoglycemia only or neither (Table 4).
Discussion
We conducted a six-year analysis of more than 66,000 individ-
ual patient admissions to 24 ICUs across Australia and New
Zealand to: describe the incidence of and clinical factors asso-
ciated with early hypoglycemia and BG variability; evaluate the
association between early hypoglycemia, BG variability and
mortality; and explore the association between severity of early
hypoglycemia and mortality.
We determined that early hypoglycemia (BG < 4.5 mmol/L) is
common, occurring in 13.8% of patients within the first day of
ICU admission alone (with 18.3% of these patients having two
episodes). This is the largest observational study to provide an
estimate of the incidence of early hypoglycemia in a general
ICU population that does not incorporate a protocol-driven
approach for maintaining TCG with IIT. In contrast, in a two-
year survey of a single center where TGC by IIT was routinely
Table 1










Age (mean [SD]) (years) 61.1 (18) 59.2 (20) 62.6 (17) 61.4 (18) <0.001
Male sex (%) 59.0 53.4 53.2 59.8 <0.001
Co-morbid disease (%) 24.2 25.7 29.8 23.8 <0.001
Cardiovascular 10.7 10.4 15.5 10.6 0.016
Respiratory 7.8 7.7 9.2 7.8 0.08
Immunocompromised 5.1 6.2 6.2 4.9 <0.001
End-stage kidney disease 3.6 6.6 7.4 3.1 <0.001
Metastatic cancer 2.8 2.7 1.8 2.8 0.03
Liver disease 2.5 4.2 3.1 2.3 <0.001
Hematologic malignancy 1.5 1.7 1.4 1.5 0.41
Non-elective admission (%) 65.9 76.9 79.8 64.1 <0.001
Surgical admission (%) 45.7 34.4 27.7 47.6 <0.001
Cardiovascular (%) 33.8 30.4 37.3 34.1 <0.001
Trauma (%) 9.3 7.4 4.3 9.7 <0.001
Primary diagnosis (%)
Sepsis/septic shock 23.0 30.4 26.6 21.9 <0.001
Respiratory 13.4 10.0 13.9 13.8 <0.001
Gastrointestinal (other) 10.5 10.4 8.1 10.6 0.025
Cardiac 10.2 9.1 19.5 10.0 <0.001
Neurologic 9.8 7.3 6.3 10.2 <0.001
Hepatic 6.3 7.6 5.2 6.2 <0.001
Metabolic/poisoning 6.8 11.6 11.2 6.1 <0.001
Gastrointestinal Bleeding 3.2 2.8 3.0 3.2 0.09
SD = standard deviation.Available online http://ccforum.com/content/13/3/R91
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applied, Vriesendorp and colleagues reported that 6.9% of
ICU admissions experienced an episode of severe hypoglyc-
emia (BG < 2.5 mol/L), with 33% of these patients having
more than one episode. [29]. In our study, severe hypoglyc-
emia (BG < 2.5 mmol/L) occurred in only 1.4% of patients
within 24 hours of ICU admission. This observation is similar
to the occurrence of severe hypoglycemia in critically ill
patients allocated to the standard/control groups in several IIT
trials. [2,4,5,9,19,30]. Conversely, in those allocated to IIT,
where routine and strict monitoring was performed, severe
hypoglycemia was surprisingly common, occurring in 5 to
19% of patients [2,4,5,9]. Moreover, the high incidence of
severe hypoglycemia (8.6 to 12.1%) in patients receiving IIT
has also justified the premature termination of two large multi-
center randomized trials of TGC in critically ill patients [19,30].
These data suggest the occurrence of hypoglycemia is far
more common than appreciated.
We found that several clinical factors were associated with a
higher occurrence of early hypoglycemia, suggesting selected
patients are at higher risk and may be identifiable. These fac-
tors included female sex, pre-morbid end-stage kidney dis-
ease, liver disease, being immune-compromised, medical or
non-elective admissions, primary diagnosis of sepsis or meta-
bolic/poisoning admission diagnoses, and greater acute
severity of illness. Additional factors predisposing to hypogly-
cemia have been identified that are more likely to be modifiable
including adjustments to nutritional support without concomi-
tant adjustment to insulin administration, use of vasoactive
medications, and use of continuous renal replacement ther-
apy. [31]. Observational data and findings from randomized tri-
als have shown that TGC with insulin therapy also represents
an independent risk factor for hypoglycemia [1,30,31].
Early hypoglycemia in our study was associated with signifi-
cantly higher ICU and hospital mortality rates, even after
adjustment for available confounding factors. Moreover, our
findings are further supported by evidence of a dose-response
gradient between the severity of hypoglycemia and mortality,
along with higher mortality associated with repeated episodes
of hypoglycemia. Although numerous studies have concluded
that TGC can positively impact the clinical outcomes in ICU
Table 2











APACHE II [mean (SD)] 17.0 (8.3) 18.9 (9.4) 22.1 (9.7) 16.2 (8.0) <0.001
APACHE III [mean (SD)] 56.7 (29.8) 65.0 (36.2) 78.1 (35.3) 55.0 (28.2) <0.001
Mechanical Ventilation (%) 45.6 49.6 55.4 44.8 <0.001
pH [mean (SD)] 7.32 (0.1) 7.30 (0.14) 7.26 (0.16) 7.33 (0.12) <0.001
Creatinine (umol/L) [median 
(IQR)]
90 (70 to 136) 100 (68 to 190) 123 (80 to 225) 90 (70 to 130) 0.001
Urea (mmol/L) [median 
(IQR)]
6.7 (4.6 to 11.2) 7.4 (4.3 to 14.8) 9.9 (6.0 to 17.7) 6.6 (4.6 to 10.6) 0.001
Urine (L/24 hr) [median 
(IQR)]
1.75 (1.04 to 2.56) 1.60 (0.84 to 2.50) 1.70 (0.85 to 2.63) 1.77 (1.08 to 2.56) 0.001
APACHE = Acute Physiology and Chronic Health Evaluation; IQR = intra-quartile range; SD = standard deviation.
Table 3










ICU length of stay (days) 
[median (IQR)]
1.9 (1.0 to 4.4) 2.0 (1.0 to 4.6) 2.7 (1.3 to 5.5) 1.9 (1.0 to 4.3) 0.001
Hospital length of stay (days) 
[median (IQR)]
10.7 (5.9 to 21.0) 10.0 (4.4 to 21.5) 11.4 (4.9 to 24.1) 10.7 (6.0 to 20.9) 0.001
ICU mortality (%) 11.1 17.3 22.6 9.8 <0.001
Hospital mortality (%) 16.9 24.3 30.7 15.5 <0.001
ICU = intensive care unit; IQR = intra-quartile range.Critical Care    Vol 13 No 3    Bagshaw et al.
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patients [1,3,5,6,32,33], the apparent benefit of narrowly reg-
ulated glycemic control and IIT may come at the expense of
increased rates of hypoglycemia. [34,35]. Data from a single
small observational study have suggested no association
between severe hypoglycemia and short-term mortality. [29].
However, Brunkhorst and colleagues [19] found that that
severe hypoglycemia was independently associated with a
higher risk of death (hazard ratio = 3.31, 95% CI = 2.23 to
4.90) with greater duration of stay in hospital [36]. This obser-
vation is more consistent with our data, suggesting that any
hypoglycemic event may portend an increase in mortality risk.
Importantly, despite data to suggest the duration of hypoglyc-
emic episodes are short (largely due to intensive monitoring).
[1,30,37], recognition may be delayed and critically ill patients
may exhibit impaired counter-regulatory responses, further
contributing to poor clinical outcome.
Table 4
Summary of crude and adjusted ICU and hospital mortality stratified by occurrence of hypoglycemia, and by blood glucose 







Crude Adjusted‡ Crude Adjusted§
Early hypoglycemia
Two episodes 1409 (2.1) 3.3 (2.9 to 3.7) 2.4 (2.0 to 2.8) 2.7 (2.4 to 3.0) 2.2 (1.9 to 2.5)
One episode only 7713 (11.7) 1.9 (1.8 to 2.1) 1.3 (1.2 to 1.4) 1.7 (1.6 to 1.8) 1.2 (1.1 to 1.3)
No hypoglycemia¶ 57062 (86.2) 1.0 1.0 1.0 1.0
BG variability
BG variability 1913 (2.9) 2.7 (2.4 to 3.0) 1.5 (1.4 to 1.6)† 2.4 (2.1 to 2.6) 1.4 (1.3 to 1.5)
Hypoglycemia 7209 (10.97) 2.0 (1.8 to 2.1) 1.2 (1.1 to 1.4)† 1.7 (1.6 to 1.8) 1.2 (1.0 to 1.4)
Neither¶ 57062 (86.2) 1.0 1.0† 1.0 1.0
APACHE = Acute Physiology and Chronic Health Evaluation; AuROC = area under the receiver operator characteristic curve; BG = blood 
glucose; CI = confidence interval; ICU = intensive care unit; OR = odds ratio.
¶Reference variable
‡ Goodness-of-fit, P = 1.0; AuROC 0.89.
§ Goodness-of-fit, P = 1.0; AuROC 0.87.
† Goodness-of-fit, P = 1.0; AuROC 0.89.
 Goodness-of-fit, P = 1.0; AuROC 0.87.
§‡† Covariate adjustment for age, sex, surgical status, primary diagnosis, co-morbid illness, non-age-related APACHE II score, mechanical 
ventilation, acute kidney injury, year, and hospital site.
Figure 1
Incidence of hypoglycemia stratified by degree of hypoglycemia within 24 hours of intensive care unit admission Incidence of hypoglycemia stratified by degree of hypoglycemia within 24 hours of intensive care unit admission.Available online http://ccforum.com/content/13/3/R91
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Since publication of the two University of Leuven IIT trials
[4,5], several additional randomized trials conducted across a
range of critically ill populations have failed to show a benefit
in survival and an increased risk of hypoglycemia with IIT com-
pared with conventional therapy. [19,30,38-40]. These data
have recently been summarized in a systematic review [18].
Moreover, the NICE-SUGAR trial has found TGC with IIT was
associated with an increased risk of death at 90 days. [9]. This
recurrent observation raises important questions about what
the optimal and safest target for BG control in critically ill
patients should be to both optimize clinical outcomes but also
prevent the adverse consequences of hypoglycemia, in partic-
ular for those with identifiable risks for hypoglycemia. Although
our study cannot directly evaluate the impact of TGC with IIT
on risk of hypoglycemia or BG variability, we believe this is a
critical issue to understand. Moreover, we would suggest that
risk modification by TGC may need to be more context spe-
cific and that not all critically ill patients may realize the per-
ceived benefits from TGC.
Although avoidance of overt (and sustained) hyperglycemia
may have recognized importance for improving clinical out-
comes in critically ill patients. [4,5,41], wide variability in glyc-
emic control is increasingly recognized as an important aspect
of BG control and has been associated with significantly
higher mortality in several observational studies. [21-
Table 5




Adjusted OR§ (95% CI)
Hospital mortality
Adjusted OR‡ (95% CI)
<2.0 4.8 (3.3 to 7.0) 3.8 (2.6 to 5.6)
2.1–2.4 2.4 (1.6 to 3.6) 2.1 (1.4 to 3.1)
2.5–2.9 1.9 (1.4 to 2.6) 1.7 (1.3 to 2.4)
3.0–3.4 2.0 (1.5 to 2.5) 1.8 (1.4 to 2.3)
3.5–3.9 1.3 (1.0 to 1.6) 1.3 (1.0 to 1.6)
4.0–4.4 1.0 (0.8 to 1.2) 1.0 (0.8 to 1.2)
≥ 4.5¶ 1.0 1.0
APACHE = Acute Physiology and Chronic Health Evaluation; AuROC = area under the receiver operator characteristic curve; CI = confidence 
interval; ICU = intensive care unit; OR = odds ratio.
¶ Reference variable
§ Goodness-of-fit, P = 1.0; AuROC 0.85.
‡ Goodness-of-fit, P = 1.0; AuROC 0.82.
§‡ Covariate adjustment for age, sex, surgical status, primary diagnosis, co-morbid illness, non-age-related APACHE II score, mechanical 
ventilation, acute kidney injury, year, and hospital site.
For conversion of blood glucose from SI to conventional units divide by 0.05551.
Table 6




Adjusted OR§ (95% CI)
Hospital mortality
Adjusted OR‡ (95% CI)
<2.0 6.0 (2.9 to 12.4) 6.4 (3.1 to 13.4)
2.1–2.4 1.2 (0.6 to 2.7) 1.2 (0.6 to 2.5)
2.5–2.9 1.7 (0.9 to 3.2) 1.9 (1.1 to 3.3)
3.0–3.4 1.8 (1.2 to 2.8) 1.7 (1.2 to 2.5)
3.5–3.9 1.6 (1.1 to 2.3) 1.5 (1.1 to 2.1)
4.0–4.4 1.1 (0.8 to 1.5) 1.1 (0.8 to 1.4)
≥ 4.5¶ 1.0 1.0
APACHE = Acute Physiology and Chronic Health Evaluation; AuROC = area under the receiver operator characteristic curve; CI = confidence 
interval; ICU = intensive care unit; OR = odds ratio.
¶ Reference variable
§ Goodness-of-fit, P = 1.0; AuROC 0.87.
‡ Goodness-of-fit, P = 1.0; AuROC 0.84.
§‡ Covariate adjustment for age, sex, surgical status, primary diagnosis, co-morbid illness, non-age-related APACHE II score, mechanical 
ventilation, acute kidney injury, year, and hospital site.
For conversion of blood glucose from SI to conventional units divide by 0.05551.Critical Care    Vol 13 No 3    Bagshaw et al.
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24,42,43]. We found early variability in BG values occurred in
2.9% of the cohort during the study period. Moreover, those
experiencing BG variability showed important differences in
several clinical characteristics when compared with those hav-
ing either hypoglycemia only or neither. For example, these
patients were generally older, had higher burden of co-morbid
disease, in particular end-stage kidney disease and cardiovas-
cular disease, and had higher illness severity and received
greater treatment intensity. More importantly, variability in BG
was associated with higher adjusted ICU and hospital mortal-
ity when compared with critically ill patients experiencing
either hypoglycemia only or neither. In a retrospective analysis
of 168,337 BG measurements performed in a cohort of 7049
critically ill patients, Egi and colleagues found variability in BG
values were independently associated with increased ICU and
hospital death and prolonged duration of ICU stay. [22]. More-
over, this study found BG variability was a more powerful pre-
dictor of outcome than average BG values. Similarly, in a
prospective observational study of 191 critical ill patients with
sepsis receiving IIT, high BG variability (measured by SD of
mean BG values) was associated with higher odds of death in
multivariable analysis. [43]. In a retrospective analysis of a
large cohort of consecutively admitted critically ill patients,
Krinsley [24] found the association between BG variability and
mortality was strongest for BG in the normal range. In these
patients, mortality for those with high BG variability (fourth
quartile) was five-fold greater when compared with those with
low BG variability (first quartile). Our data would appear to
support and extend the findings of these prior investigations
by showing that early variability in BG control may negatively
impact outcome.
We recognize that there are important limitations to our study
that merit discussion. First, our study is observational, not ran-
domized, and is therefore potentially susceptible to bias. Sec-
ond, we only have available BG values during the first 24 hours
of ICU admission. Third, the APD does not capture data on
additional factors that may have relevance and, therefore we
are unable to comment on whether these modified the risk of
early hypoglycemia or BG variability (i.e. early nutritional sup-
port, dextrose administration, oral hypoglycemic medications,
insulin therapy, or concomitant corticosteroid therapy) and on
how, if at all, the hypoglycemia was treated. Thus, we are una-
ble to discriminate early hypoglycemia attributable to the pri-
mary diagnosis and illness severity rather than TGC with IIT. It
is likely the majority of hypoglycemic episodes in this study
were attributable to the primary underlying diagnosis/illness
severity rather than IIT. Fourth, we believe that the clinical out-
comes associated with BG control in critically ill patients may
be modified by pre-existing diabetes [37]; however, we were
unable to identify the diabetes subgroup for this study. We
recognize this may have been relevant for those patients with
BG variability. Fifth, due to our large database many compari-
sons between groups, in particular for physiologic and labora-
tory data, achieved statistical significance; however, in many
instances these differences have questionable or no clinical
relevance (Table 1). Finally, we were unable to evaluate sec-
ondary outcome measures (i.e. renal replacement therapy, crit-
ical illness neuromuscular complications, nosocomial
infections) or data on the potential long-term sequelae of early
hypoglycemia or BG variability on outcomes (i.e. cognitive
function, survival). We recognize these clinical outcomes have
relevance [44,45]. However, we believe our study is strength-
ened by the large cohort and by the observation of a dose-
response gradient and consistency between severity of early
hypoglycemia and mortality across several a priori planned
subgroups.
Conclusions
In critically ill patients, both early hypoglycemia and BG varia-
bility are common, and portend an increased risk of mortality.
These observations imply early hypoglycemia and BG variabil-
ity have clinical relevance and need further evaluation in the
context of protocol-driven tight-glycemic control.
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Key messages
￿  Early hypoglycemia is very common, occurring in an 
estimated 14% of critically ill patients.
￿  Several factors were associated with higher risk for 
early hypoglycemia including: female sex, pre-morbid 
end-stage kidney disease, liver disease, immune-com-
promise, medical or non-elective admissions, sepsis or 
metabolic/poisoning, and greater acute severity of ill-
ness. These patients are potentially identifiable factors.
￿  Early hypoglycemia was associated with clinically rele-
vant increases in ICU and hospital mortality rates, even 
after adjustment for available confounding factors.
￿  Early BG variability was relatively common, occurring in 
2.8% of all patients admitted to ICU during the study 
period, and was associated with higher adjusted mortal-
ity when compared with patients with either hypoglyc-
emia alone or neither.
￿  These findings, although limited, imply early hypoglyc-
emia and BG variability have clinical relevance and need 
further evaluation in the context of protocol-driven tight-
glycemic control.Available online http://ccforum.com/content/13/3/R91
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